Skip to main content
All Posts By

laurabbook@gmail.com

Dr. Benjamin Herzberg
ResearchStories

Clinician Spotlight: Dr. Benjamin Herzberg

*February 2024* This month we have the honor of featuring Dr. Benjamin Herzberg MD, who is a medical oncologist at Columbia University, Herbert Irving Comprehensive Cancer Center in New York. Dr. Herzberg attended the 2023 EGFR Resisters Research Summit and was awarded the Distinguished Young Investigator for his work, ATR Inhibitors…
laurabbook@gmail.com
March 20, 2024
JTO Clinical and Research Reports
ResearchTreatments

Brief Report: Comprehensive Clinicogenetic Profiling of Small Cell Transformation from EGFR-mutant NSCLC Informs Potential Therapeutic Targets

*December 2023* Introduction NSCLC transformation to SCLC has been best characterized with EGFR-mutant NSCLC, with emerging case reports seen in ALK, RET, and KRAS-altered NSCLC. Previous reports showed transformed SCLC from EGFR-mutant NSCLC portends very poor prognosis and lack effective treatment. Genomic analyses showed TP53 and RB1 loss of function increase the risk of SCLC transformation. Little has been…
laurabbook@gmail.com
March 20, 2024
OncLive
ResearchTreatments

sBLA and NDA Submitted to FDA for Amivantamab and Lazertinib in EGFR-Mutant NSCLC

*December 2023* Note: Amivantamab and Lazertinib may soon receive approval as a first-line treatment for EGFR+ lung cancer. A supplemental biologics license application and new drug application seeking the approval of amivantamab-vmjw (Rybrevant) plus lazertinib as frontline therapy for the treatment of patients with locally advanced or metastatic non–small cell lung…
laurabbook@gmail.com
March 20, 2024
Medical Xpress
ResearchTreatments

Overcoming drug resistance with EAI-432, an allosteric EGFR inhibitor for non-small cell lung cancer

*November 2023* Note: Allosteric inhibitors are an exciting new possibility to treat osimertinib resistance but are still in preclinical stage of development. Researchers at Dana-Farber Cancer Institute have developed a promising new drug candidate, EAI-432, to treat non-small cell lung cancers (NSCLC)driven by mutations in the EGFR gene, particularly the L858R mutation…
laurabbook@gmail.com
March 19, 2024
Dr. Laura Petrillo
ResearchStories

Clinician Spotlight: Dr. Laura Petrillo

*January 2024* This month we have the honor of featuring Dr. Laura Petrillo, MD.  Dr. Petrillo is a palliative care physician-investigator in the Division of Palliative Care and Geriatrics at Massachusetts General Hospital and an Assistant Professor of Medicine at Harvard Medical School  Dr. Petrillo attended the 2021 EGFR Resisters…
laurabbook@gmail.com
March 19, 2024